• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.01%

    Agenus Inc. (AGEN)

    8.54 Up 0.15(1.79%) Jul 31, 4:00PM EDT
    |After Hours : 8.54 0.00 (0.00%) Jul 31, 4:43PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Agenus Inc.
    3 Forbes Road
    Lexington, MA 02421
    United States - Map
    Phone: 781-674-4400
    Fax: 781-674-4200
    Website: http://www.agenusbio.com

    Index Membership:N/A
    Full Time Employees:131

    Business Summary 

    Agenus Inc., an immunotherapy company, engages in discovering and developing innovative treatments for patients with cancer and other diseases. Its treatments focus on providing therapeutic benefit through modulation of immune function. The company offers Retrocyte Display, a platform that screens and generates therapeutic antibody drug candidates focused on advancing checkpoint modulators using a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lymphocytes. It is also developing heat shock protein vaccine, which is in Phase II studies for treating cancer and infectious diseases; and QS-21 Stimulon, a saponin-based vaccine adjuvant for use in pre-clinical and clinical stage vaccine programs that target prophylactic or therapeutic impact in a range of infectious diseases and cancer. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Agenus Inc.

    Corporate Governance 
    Agenus Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Garo H. Armen Ph.D., 62
    Founder, Exec. Chairman, Chief Exec. Officer and Chairman of Bus. & Devel. Advisory Committee
    Ms. Christine M. Klaskin , 49
    Principal Accounting Officer and VP of Fin.
    Dr. Robert B. Stein M.D., Ph.D., 64
    Chief Scientific Officer
    Ms. Karen Higgins Valentine J.D., 43
    Chief Compliance Officer, Chief Legal Officer and Sec.
    Mr. Ozer Baysal , 59
    Chief Bus. Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders